Ethiopia is experiencing its first recorded outbreak of the deadly Marburg virus, unfolding amid political unrest, ...
The training brought together journalists, scientists, and health communicators to deepen their understanding of vaccines, ...
The 2025–26 respiratory syncytial virus (RSV) season is shaping up to be a pivotal moment in the fight against this significant global health threat. In just the past 2 years, three products have been ...
Prior exposure to coronaviruses that cause ordinary colds can boost the immune system's ability to attack a vulnerable site ...
A first-in-human Phase 1 clinical trial of IAVI’s Lassa virus (LASV) vaccine candidate has shown encouraging results, ...
Learn about Rift Valley Fever's impact, outbreaks, transmission, and global response strategies to manage this zoonotic ...
The global vaccines market is projected to grow from USD 50.46 billion in 2025 to USD 63.66 billion by 2030, achieving a CAGR ...
Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...
Commitment to U.S. Manufacturing – GeoVax is advancing continuous cell line manufacturing to expand supply, reduce costs, and support U.S. preparedness, aligning with federal initiatives to strengthen ...
IAVI reports its single-dose Lassa fever vaccine is safe and effective, paving way for advanced trials across West Africa.
Volunteers were monitored for 12 months post-vaccination, with immune responses activating both humoral and cellular immunity ...
A Lassa fever vaccine candidate was safe and produced a strong immune response in adults in the United States and Liberia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback